Non-Steroidal Anti-inflammatory Drugs Global Market Report 2024

The global non-steroidal anti-inflammatory drugs market has grown strongly in recent years. It will grow from $19.56 billion in 2023 to $20.93 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth observed in the historical period can be attributed to various factors, including the prevalence of chronic inflammatory diseases, the need for effective postoperative pain management, incidents related to sports injuries, the availability of over-the-counter options, the aging population, and increased consumer awareness regarding pain management.

The global non-steroidal anti-inflammatory drugs market is expected to see strong growth in the next few years. It will grow to $27.09 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The anticipated growth in the upcoming period is attributed to the emergence of new pain management therapies, regulatory shifts affecting the landscape, increased utilization of telehealth services, global trends emphasizing wellness, competition driven by biosimilars, evolving patient preferences, and the implementation of precision medicine strategies in pain management. Key trends expected in this period encompass the dominance of the over-the-counter (OTC) market, a growing preference for COX-2 inhibitors, intensifying competition within generics markets, and the integration of digital health technologies into pain management solutions, emphasizing the significance of digital health tools in enhancing care delivery.

The rising incidence of chronic pain is anticipated to drive the expansion of the non-steroidal anti-inflammatory drugs (NSAIDs) market. Chronic pain, persisting for over six months, finds treatment through NSAIDs, which aid in healing injuries and managing prolonged discomfort. As per the CDC's April 2022 report, arthritis stands as a leading cause of chronic pain, affecting millions in the US. A significant percentage of arthritis patients, estimated at one in four adults, endure severe joint pain, underlining the pivotal role of NSAIDs in managing chronic pain and driving the market's growth.

Increasing prevalence of musculoskeletal disorders (MSDs) is set to fuel the growth of the NSAIDs market. MSDs encompass a range of conditions impacting the musculoskeletal system and often requiring pain and inflammation management, for which NSAIDs serve as key therapeutic agents. Factors like an aging demographic, enhanced disease awareness, and greater orthopedic interventions contribute to this surge. A profile by GOV.UK in December 2022 highlighted the upsurge in the prevalence of MSDs among UK individuals aged 16 and above, pointing to a rise from 2021. This escalation underscores the market's trajectory, propelled by the increasing burden of musculoskeletal conditions and the role of NSAIDs in their management.

Innovative product development remains a prominent trend in the NSAIDs market. Key industry players focus on introducing novel technology-driven solutions to enhance their market standing. For example, in May 2021, Ono and Seikagaku, a Japan-based firm operating in NSAIDs, launched JOYCLU, a 30 mg intra-articular injection. This product leverages Seikagaku's technology, binding hyaluronic acid with diclofenac, releasing the medication within the joint through hydrolysis. Positioned for osteoarthritis treatment, its intra-articular administration minimizes systemic exposure to diclofenac, reducing the risk of systemic adverse reactions. JOYCLU represents a pioneering osteoarthritis joint function improvement agent in Japan.

Industry leaders in the NSAIDs market are pursuing new combination therapies to gain competitive advantages. Combination therapies entail the simultaneous use of multiple therapeutic agents or treatments to amplify efficacy or address diverse facets of a condition. For instance, in August 2022, Haleon PLC, a UK-based consumer healthcare company, introduced Advil PLUS Acetaminophen in Canada. This tablet combines ibuprofen and acetaminophen, providing a dual mechanism for pain relief across various pain types. The fusion of these two agents in a single tablet offers an accessible, non-prescription option for pain management, ensuring prolonged relief for up to eight hours. Advil PLUS Acetaminophen stands as an over-the-counter solution available in multiple retail outlets in Canada, showcasing the market's emphasis on effective combination therapies.

In March 2022, Pfizer, a prominent U.S.-based pharmaceutical and biotechnology company, acquired Arena Pharmaceuticals for an undisclosed sum. This strategic move enables Pfizer to access Arena Pharmaceuticals' diverse pipeline of developmental-stage therapeutic candidates primarily focused on dermatology, gastroenterology, and cardiology. Notably, this includes etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently undergoing development for various immuno-inflammatory diseases like Crohn's disease, ulcerative colitis, atopic dermatitis, eosinophilic esophagitis, and alopecia. Arena Pharmaceuticals, a U.S.-based company specializing in non-steroidal anti-inflammatory drugs, brings this portfolio of innovative treatments to Pfizer through this acquisition.

Major companies operating in the non-steroidal anti-inflammatory drugs market report are Pfizer Inc., Bayer AG, Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Assertio Therapeutics Inc., Iroko Pharmaceuticals Inc., Reckitt Benckiser Group PLC, Perrigo Company PLC, Hikma Pharmaceuticals Public Limited Company, Glenmark Pharmaceuticals Limited, Septodont, Aspen Pharmacare Holdings Limited, Sagent Pharmaceuticals Inc., Advanced Pharma Inc., Akorn Operating Company LLC, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Zydus Cadila Healthcare Limited, Aurobindo Pharma Limited, Sanofi S.A., GlaxoSmithKline PLC, Horizon Therapeutics PLC, Zyla Life sciences, Novartis AG, Roche Holding AG, AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company

North America was the largest region in the non-steroidal anti-inflammatory drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the non-steroidal anti-inflammatory drugs market during the forecast period. The regions covered in the non-steroidal anti-inflammatory drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-steroidal anti-inflammatory drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Administration of these drugs primarily occurs through oral ingestion, topical application, and other alternative methods. Topical application is particularly effective in alleviating muscle pains, sprains, and strains, offering relief for painful arthritic conditions. NSAIDs cater to a spectrum of disease indications encompassing arthritis, migraines, ophthalmic disorders, and other related ailments, being accessible through hospital pharmacies, retail outlets, and online pharmacy platforms.

This report provides non-steroidal anti-inflammatory drugs market statistics, including non-steroidal anti-inflammatory drugs industry global market size, regional shares, competitors with a non-steroidal anti-inflammatory drugs market share, detailed non-steroidal anti-inflammatory drugs market segments, market trends and opportunities, and any further data you may need to thrive in the non-steroidal anti-inflammatory drugs industry. The non-steroidal anti-inflammatory drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-steroidal anti-inflammatory drugs market consists of sales of high-dose aspirin, indomethacin, mefenamic acid, celecoxib, and other types. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.